No Data
No Data
Guangyuyuan Chinese Herbal Medicine (600771.SH): The product, Dingkun Dan, has been included in the national medical insurance pharmaceutical directory, while Guilin Jie has not been included yet.
Guangyuyuan (600771.SH) stated on the investor interaction platform on August 16th that currently the company's Dingkun Dan product has been included in the National Medical Insurance Pharmaceutical Catalog, while Gui Ling Ji is not yet included.
Guangyuyuan (600771.SH): Angong Niuhuang Pill is a recommended treatment drug in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia.
Guangyuyuan (600771.SH) stated on the investor interaction platform on August 16th that the company's product, Angong Niuhuang Pill, is a recommended treatment drug in the Diagnosis and Treatment Scheme of Novel Coronavirus Pneumonia. Disease prevention requires enhancing physical fitness and improving overall body functions. Products that help strengthen the body and replenish qi can be selected under the guidance of a doctor.
Guangyuyuan Chinese Herbal Medicine (600771.SH): Has not yet tried to transform towards new tracks.
On August 5th, Gelonhui reported that Guangyuyuan (600771.SH) is currently focusing on its main responsibilities and carrying out various tasks around its four core products in marketing breakthroughs. Regarding the innovative development of traditional Chinese medicine, based on mature and precise product formulation, processes, and efficacy, the company adheres to the fundamental principle of maintaining strict selection of materials and stable quality while conducting secondary product development without changing the guiding principles of advantages and high quality, and continuously launching high-quality traditional Chinese medicine products and related services while focusing on safety, effectiveness, and quality controllability. The company has not yet attempted a new transformation of its business model and also has not yet invested heavily nor developed in the direction of the new market.
Guangyuyuan Chinese Herbal Medicine (600771.SH): The company has no direct overseas business.
Guangyuyuan (600771.SH) stated on the investor interaction platform on August 5th that the company has no direct overseas business and the exchange rate fluctuations do not have a direct impact on the company's finances for the time being.
Guangyuyuan Chinese Herbal Medicine (600771.SH) has not cooperated with Huawei.
On July 25th, Gelonhui reported that Guangyuyuan chinese herbal medicine (600771.SH) stated on the investor communication platform that the company currently has no cooperation with Huawei. The construction of other brands is currently underway.
As GuangYuYuan Chinese Herbal Medicine (SHSE:600771) Ascends 4.8% This Past Week, Investors May Now Be Noticing the Company's Three-year Earnings Growth
No Data